pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cancer Program · news · pharmadog
← back to Cancer Program
News mentioning Cancer Program
197
stories
22d
AstraZeneca cuts early-phase prostate cancer pipeline
fiercebiotech
22d
R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program
endpoints
22d
Genmab soars to record highs after cancer drug succeeds in key trial
biopharma dive
22d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
22d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
22d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
23d
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
biospace
23d
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
biospace
23d
Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3
fiercebiotech
24d
STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
stat
25d
Opinion: Cancer vaccines are finally here. How do we get them to patients?
stat
25d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
25d
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
biospace
25d
STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
stat
25d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
26d
#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons
endpoints
27d
STAT+: After a cancer vaccine’s first success, the race is on to expand the impact
stat
27d
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
endpoints
28d
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
fiercebiotech
28d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
28d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
29d
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
biospace
29d
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
biopharma dive
Oct 22, 26
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
Oct 21, 26
ESMO: After leak, Merck and Moderna post phase 3 cancer vaccine data early
fiercebiotech
Oct 20, 26
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
Oct 20, 26
Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
biospace
Oct 19, 26
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
biospace
Oct 19, 26
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
biospace
Oct 15, 26
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
stat
← prev
page 2 of 7
next →